Please click here to visit the American Regent site.		 American Regent, Inc.


It was almost 40 years ago that a group of dedicated professionals got together with an idea for a new company. However, it is unlikely any of these people imagined what that company would become in the future. Since then, Luitpold Pharmaceuticals and American Regent have become industry leaders in the development, manufacture, and distribution of more than 130 quality injectable products representing 65 different chemical entities. In particular, American Regent's flagship iron-based product, Venofer ® (iron sucrose injection, USP) — launched in November 2000 — is the number one prescribed intravenous iron product in the United States and represents an important advance in the safe treatment of iron deficiency anemia in hemodialysis patients on erythropoietin therapy.

From the beginning, American Regent has remained committed to quality and the highest standards of customer service. The professionals at American Regent continue to work closely with the healthcare community to be the company of choice when it comes to injectable products. In addition, American Regent strives to provide top-of-the-line customer service. After all, when you call American Regent, a real person will always answer the phone — not an automated voice mail system.

Since 1967, American Regent has been synonymous with quality. American Regent may have started small, but the company has maintained a steady growth; today we are one of the premier suppliers of injectable products to hospitals, pharmacies, and clinics throughout the United States.

To learn more about Venofer®, click here.
To learn more about American Regent, click here.

Venofer® is manufactured under license from Vifor (International) Inc., Switzerland

Important Safety Information
Venofer® (iron sucrose injection, USP) is contraindicated in patients with evidence of iron overload, in patients with known hypersensitivity to Venofer® or any of its inactive components, and in patients with anemia not caused by iron deficiency. Hypersensitivity reactions have been reported with IV iron products. Hypotension has been reported frequently in hemodialysis dependent CKD patients receiving IV iron, and, has also been reported in non-dialysis dependent-CKD patients receiving IV iron. Hypotension following administration of Venofer® may be related to rate of administration and total dose delivered.

In multi-dose efficacy studies in hemodialysis dependent-CKD patients (N=231), the most frequent adverse events (>5%), whether or not related to Venofer® administration, were hypotension, cramps/leg cramps, nausea, headache, graft complications, vomiting, dizziness, hypertension, chest pain and diarrhea. In post-marketing safety studies in hemodialysis dependent-CKD patients (N=1051), the most frequent adverse events reported (>1%) were congestive heart failure, sepsis and taste perversion. In the multi-dose efficacy study in non-dialysis dependent-CKD patients (N=91), the most frequent adverse events (>5%) whether or not related to Venofer® administration, were taste disturbance, peripheral edema, diarrhea, constipation, nausea, dizziness, and hypertension.

© 2005, Luitpold Pharmaceuticals, Inc. Terms of Use | Privacy Policy